NovoCure Limited — Q1 2024 Form 10-Q
Business context and period. The unaudited quarter ended March 31, 2024. NovoCure develops and commercializes Tumor Treating Fields (TTFields) devices, principally Optune Gio for glioblastoma and Optune Lua for mesothelioma. The company reported one operating segment.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net revenue | $138.5 million | $122.2 million | +13% |
| Gross profit / margin | $104.8 million / 76% | $92.6 million / 76% | Gross profit +13% |
| Operating loss | $(41.5) million | $(60.2) million | Loss narrowed |
| Net loss | $(38.8) million | $(53.1) million | Loss narrowed |
| Loss per share, diluted | $(0.36) | $(0.50) | Improved |
| Adjusted EBITDA (non-GAAP) | $(4.6) million | $(18.4) million | Improved by $13.8 million |
| Cash used in operating activities | $(31.6) million | $(16.7) million | Use increased $14.8 million |
Revenue growth reflected the France launch ($10.5 million, per management) and higher U.S. revenue, including $4.2 million from prior-period claims following improved approval rates. Revenue by region was $90.5 million in the U.S., $43.0 million in international markets excluding Greater China, and $4.9 million in Greater China. Cost of revenue rose 14%; cost per active patient per month, excluding Zai sales, increased 4% to $2,715, primarily due to next-generation arrays. Management reported gross margin of 76% in both periods.
Research, development and clinical study expense fell 14% to $51.6 million, mainly on lower personnel and direct trial costs. Sales and marketing expense rose 8% to $55.2 million, including sales-force expansion and preparation for a potential NSCLC launch. General and administrative expense fell 6% to $39.5 million. Net financial income was $9.9 million; income tax expense was $7.1 million.
Financial position and liquidity
- At March 31, cash and cash equivalents were $453.8 million and short-term investments were $416.4 million, totaling $870.1 million; this was down from $910.6 million at December 31, 2023. Cash, cash equivalents and restricted cash totaled $457.4 million.
- Current assets were $1,002.7 million and current liabilities $160.2 million. Trade receivables were $65.1 million and inventories $42.4 million.
- Long-term debt, net, was $569.7 million, representing the $575 million principal amount of 0% convertible senior notes due November 2025, less unamortized issuance costs. The notes were not convertible as of quarter-end. The notes’ stated effective interest rate is 0.59%.
- Net cash used in operating activities was $31.6 million. Investing activities provided $246.2 million, principally from $258.0 million of investment maturities, offset by $11.8 million of property and equipment purchases; this is not operating cash generation.
- Accumulated deficit was $1,024.3 million. Management said available cash and short-term investments were sufficient for at least the next 12 months under its existing plan, while noting that operating expenses may increase and may outpace gross profit.
Material changes and outlook
- Active patients at quarter-end rose to 3,845 from 3,467 a year earlier; U.S. patients declined to 2,137 from 2,168, while international patients increased to 1,708 from 1,299. Prescriptions received increased to 1,643 from 1,496.
- Management attributed the improvement in adjusted EBITDA to revenue growth and operating efficiencies following the November 2023 restructuring, which included a planned workforce reduction of approximately 200 employees, or 13%. Q1 restructuring costs were $2.0 million before specified accrual and share-based compensation reversals.
- No numerical financial guidance was provided. Management expects operating expenses to continue increasing over the next several years as it pursues additional indications and says it will prioritize growth while maintaining financial flexibility.
- After quarter-end, on May 1, 2024, a subsidiary entered a five-year secured credit facility of up to $400 million and received an initial $100 million draw. A further $100 million draw is required by June 30, 2025, subject to customary conditions; additional draws are conditional. Interest is 6.25% plus three-month SOFR, subject to a 3.25% SOFR floor. The facility is secured by a first lien on specified assets and carries draw fees and prepayment provisions.
Clinical, regulatory and other risks
- The FDA accepted the NSCLC PMA application based on the LUNAR study; NovoCure anticipated an FDA decision in the second half of 2024. Applications were also filed in Europe and Japan. The new arrays were rolling out in parts of Europe; a U.S. PMA supplement remained under review.
- The phase 3 METIS trial met its primary endpoint for time to intracranial progression: median 21.9 months versus 11.3 months, hazard ratio 0.67, p=0.016. Preliminary analyses of key secondary endpoints did not show statistical significance.
- Management said there was no immediate risk to facilities or operations from the Israel conflict, while noting efforts to increase supply stocks to mitigate supplier and distribution risks.
- A putative securities class action alleges misstatements or omissions concerning LUNAR trial results. NovoCure disputes the claims; it recorded no accrual because liability was not considered probable and the amount could not be reasonably estimated.
- The filing identifies ongoing risks including clinical and regulatory outcomes, adoption and reimbursement, product supply and manufacturing, and the possibility of additional financing needs. Management reported no material changes to the risk factors in its 2023 Form 10-K.
Important facts for investors to verify
- Whether revenue growth, patient additions and U.S. approval-rate improvements persist, and how much revenue relates to prior-period claims or new-market launches.
- Whether operating cash use and expenses remain elevated, given the quarter’s working-capital outflow and the company’s continuing net losses.
- Timing and outcome of the NSCLC PMA review, and full METIS results and progress of other major trials, including PANOVA-3.
- Funding conditions, costs, collateral, repayment terms and covenant triggers for the post-quarter credit facility, alongside the 2025 convertible note maturity.
- Developments in the LUNAR-related lawsuit and any changes to management’s stated liquidity outlook or supply-chain assessment.